Stock FENNEC PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights Fennec Pharmaceuticals Inc. Nasdaq

Equities

CA31447P1009

Real-time Estimate Cboe BZX
Other stock markets
 11:08:14 2024-06-10 am EDT 		5-day change 1st Jan Change
6.88 USD 0.00% Intraday chart for Fennec Pharmaceuticals Inc. 0.00% 0.00%
May. 15 HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating MT
May. 14 Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue
MT
Fennec Pharmaceuticals Brief: Company Says Has Approximately US$51 Million in Cash, Cash Equivalents, and Investment Securities
MT
Fennec Pharmaceuticals Brief: Achieved Q1 2024 Total Net Revenues of US$25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction
MT
Fennec Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Wedbush on Fennec's Q4
MT
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share
MT
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million
MT
Fennec Pharmaceuticals Brief: Achieved PEDMARK Full-Year 2023 Net Product Sales of US$21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023
MT
North American Morning Briefing : Investors -2-
DJ
Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively
MT
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Fennec Pharmaceuticals, Norgine in Exclusive Licensing Agreement to Commercialize Pedmarqsi in Europe, Australia, and NZ
MT
Fennec Pharmaceuticals Brief: Fennec Pharmaceuticals and Norgine Over the Weekend Entered into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
MT
Fennec Pharmaceuticals Inc. and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
CI
Fennec Pharmaceuticals Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023
CI
Fennec Pharmaceuticals Brief: Full-year 2023 net revenues are expected to be approximately US$20.7 to $21.2 million
MT
Fennec Pharmaceuticals Brief: Q4 2023 net revenues are expected to be approximately US$9.2 to $9.7 million, which represents approximately a 41-49% increase over the third quarter of 2023
MT
Wedbush Maintains Outperform on Fennec Pharmaceuticals
MT
FDA Issues Reminder of Non-Substitution of Fennec Pharmaceuticals' Pedmark For Pediatric Patients Receiving Cisplatin
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FENC Stock
  4. Stock
  5. News Fennec Pharmaceuticals Inc.
  6. Highlights